© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
Affiliations of authors: J. J. Carter, M. M. Madeleine, G. C. Wipf, D. A. Galloway, Fred Hutchinson Cancer Research Center, Seattle, WA; R. L. Garcea, Section of Pediatric Hematology/Oncology, University of Colorado School of Medicine, Denver; P. A. Pipkin, P. D. Minor, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.
Correspondence to: Denise A. Galloway, PhD, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Rm. C1-105, PO Box 19024, Seattle, WA 98109-1024 (e-mail: dgallowa{at}fhcrc.org).
Background: Propagation of poliovirus in monkey kidney cells led to the inadvertent contamination of poliovirus vaccines with simian virus 40 (SV40) between 1955 and 1963. Recent studies using polymerase chain reaction–based strategies have detected SV40 DNA in a large number of tumor types. The finding of SV40 DNA in tumors from individuals who are too young to have been exposed to SV40-contaminated vaccines has led to the suggestion that SV40 has become a prevalent transmissible human pathogen. To test this hypothesis, we screened human sera for antibodies to SV40 using direct and competitive enzyme-linked immunosorbent assays (ELISAs). Methods: An ELISA was developed using recombinant SV40 virus-like particles (VLPs) and was validated using sera from naturally infected macaques. VLPs of SV40 and the related ubiquitous human polyomaviruses, JCV and BKV, were used to screen human sera to determine the prevalence of SV40, JCV, and BKV antibodies among a normal population of control subjects (n = 487) and among case patients with either osteosarcoma (n = 122) or prostate cancer (n = 90). A competitive ELISA in which sera were pre-adsorbed with each type of VLP was used to identify cross-reactive antibodies. Correlations of reactivity among the three polyomavirus types were calculated using the Spearman correlation coefficient. All statistical tests were two-sided. Results: BKV and JCV antibodies were prevalent in all case patients and control subjects examined. In contrast, only 6.6% (46/699) of serum samples were positive for SV40 antibodies by ELISA; however, none of these samples could be confirmed as having authentic SV40 antibodies following pre-adsorption with JCV or BKV VLPs. Conclusion: These data indicate that some individuals have BKV and/or JCV antibodies that cross-react with SV40, but they do not provide support for SV40 being a prevalent human pathogen.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
- Regis A. Vilchez and Janet S. Butel
J Natl Cancer Inst 2004 96: 633.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
- Denise A. Galloway and Joseph J. Carter
J Natl Cancer Inst 2004 96: 633-634.[Extract] [Full Text] [PDF]
- More About: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
- Frank J. O’Neill and John E. Greenlee
J Natl Cancer Inst 2004 96: 634-635.[Extract] [Full Text] [PDF]
- RESPONSE: More About: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
- Denise A. Galloway and Joseph J. Carter
J Natl Cancer Inst 2004 96: 635.[Extract] [Full Text] [PDF]
- Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
- Giuseppe Barbanti-Brodano, Alfredo Corallini, Roberto S. Accolla, Fernanda Martini, and Mauro Tognon
J Natl Cancer Inst 2004 96: 803-804.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans
- Denise A. Galloway and Joseph J. Carter
J Natl Cancer Inst 2004 96: 804-805.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  D. L. Poulin and J. A. DeCaprio Is There a Role for SV40 in Human Cancer? J. Clin. Oncol., September 10, 2006; 24(26): 4356 - 4365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Rollison, E. A. Engels, N. A. Halsey, K. V. Shah, R. P. Viscidi, and K. J. Helzlsouer Prediagnostic Circulating Antibodies to JC and BK Human Polyomaviruses and Risk of Non-Hodgkin Lymphoma. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cantalupo, A. Doering, C. S. Sullivan, A. Pal, K. W. C. Peden, A. M. Lewis, and J. M. Pipas Complete Nucleotide Sequence of Polyomavirus SA12 J. Virol., October 15, 2005; 79(20): 13094 - 13104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lundstig, L. Eliasson, M. Lehtinen, K. Sasnauskas, P. Koskela, and J. Dillner Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles J. Gen. Virol., June 1, 2005; 86(6): 1703 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Rollison, K. J. Helzlsouer, N. A. Halsey, K. V. Shah, and R. P. Viscidi Markers of Past Infection with Simian Virus 40 (SV40) and Risk of Incident Non-Hodgkin Lymphoma in a Maryland Cohort Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1448 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Engels, R. P. Viscidi, D. A. Galloway, J. J. Carter, J. R. Cerhan, S. Davis, W. Cozen, R. K. Severson, S. de Sanjose, J. S. Colt, et al. Case-Control Study of Simian Virus 40 and Non-Hodgkin Lymphoma in the United States J Natl Cancer Inst, September 15, 2004; 96(18): 1368 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Engels, J. Chen, R. P. Viscidi, K. V. Shah, R. W. Daniel, N. Chatterjee, and M. A. Klebanoff Poliovirus Vaccination during Pregnancy, Maternal Seroconversion to Simian Virus 40, and Risk of Childhood Cancer Am. J. Epidemiol., August 15, 2004; 160(4): 306 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. M. Rollison, W. F. Page, H. Crawford, G. Gridley, S. Wacholder, J. Martin, R. Miller, and E. A. Engels Case-Control Study of Cancer among US Army Veterans Exposed to Simian Virus 40-contaminated Adenovirus Vaccine Am. J. Epidemiol., August 15, 2004; 160(4): 317 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Barbanti-Brodano, A. Corallini, R. S. Accolla, F. Martini, and M. Tognon Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, May 19, 2004; 96(10): 803 - 804. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Galloway and J. J. Carter RESPONSE: Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, May 19, 2004; 96(10): 804 - 805. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Vilchez and J. S. Butel Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, April 21, 2004; 96(8): 633 - 633. [Full Text] [PDF]
|
|
|
|
|
|
F. J. O'Neill and J. E. Greenlee More About: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, April 21, 2004; 96(8): 634 - 635. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Galloway and J. J. Carter RESPONSE: More About: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, April 21, 2004; 96(8): 635 - 635. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Galloway and J. J. Carter RESPONSE: Re: Lack of Serologic Evidence for Prevalent Simian Virus 40 Infection in Humans J Natl Cancer Inst, April 21, 2004; 96(8): 633 - 634. [Full Text] [PDF]
|
|